Fig. 3
From: TGF-β induced reprogramming and drug resistance in triple-negative breast cells
TGF-β induced reprogramming promotes drug resistance. A Volcano plot of resistance marker genes (blue) and DOX-resistance marker genes (purple). DOX, doxorubicin. Resistance marker genes: EGFR, NGFR, WNT5A, SERPINE1, POSTN, PDGFRB, NRG1, VEGFC, FOSL1, RUNX2, AXL, LOXL2, FGFR1, JUN, PDGFC, GAPDH, VGF, FGFR1, PDGFC, WNT5A, MITF, SOX10. DOX-resistance marker genes: ABCB1, AC011525.2, ADAMTS1, ADD2, ANGPT1, AP4E1, BACE1, BBS12, BMP2, BMP7, BRWD1, CISH, CMPK1, CRYBG2, CST1, CYP27A1, FAAH, FAT4, FMO2, FOXJ1, GJA5, HS3ST1, KRT40, LIMA1, MCPH1, NAV2, NSG2, P2RY6, PSG4, PTPRH, SLC38A2, SNTB1, STMN2, TIMP2, TRG-AS1, TXNDC17, TYMP, ZNF503. B Fold change in expression of resistance marker genes. C Fold change in expression of DOX-resistance marker genes. D Transcriptional factors of up-regulated genes based on cis-regulatory sequence analysis